In Australia, the three tumor markers—ER, PR and HER2 are routinely used in the diagnostic workup of breast cancer because of their utility in prognosis and guiding treatment [21], given some analytical problems with Ki67 measurement and standardisation. Here, MKI67 is linked to neoplasm.